Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
3 GLP-1 Stocks to Buy Now For Big Long-Term Gains
09:12am, Sunday, 01'st Sep 2024
The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive.
Why Is Glaxo (GSK) Up 10.3% Since Last Earnings Report?
12:37pm, Friday, 30'th Aug 2024
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?
GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years
02:30pm, Thursday, 29'th Aug 2024
The European Commission approves GSK's RSV vaccine, Arexvy, for use in adults aged 50-59 years with increased risk of the disease.
GSK Stock Gains 18.5% Year to Date: Time to Buy, Sell or Hold?
10:15am, Thursday, 29'th Aug 2024
GSK's cheap valuation, reasonable stock price appreciation and bright growth potential indicate that investors should stay invested.
GSK: European Union approves label expansion for RSV jab
03:19am, Thursday, 29'th Aug 2024
The European Commission has approved the expanded use of GSK PLC (LSE:GSK, NYSE:GSK)'s Arexvy, its respiratory syncytial virus (RSV) vaccine, to include adults aged 50 to 59 at increased risk due to u
GSK shares jump on win in Delaware court over ongoing Zantac battle
06:22am, Wednesday, 28'th Aug 2024
GSK shares jumped Wednesday on news Delaware's top court ruled in the pharmaceutical company's favor, by agreeing to review the admissibility of expert evidence that could play a part in the British f
GSK shares higher after Delaware Zantac ruling
03:28am, Wednesday, 28'th Aug 2024
GSK PLC (LSE:GSK, NYSE:GSK) shares opened higher after Delaware's Supreme Court said it will hear an appeal by the UK drug market and other pharmaceutical companies, including Pfizer, Sanofi, and Boeh
GSK's ADC Drug for Lung Cancer Gets FDA's Breakthrough Tag
11:20am, Tuesday, 20'th Aug 2024
The FDA bestows a Breakthrough Therapy Designation to GSK's B7-H3-targeted antibody-drug conjugate, GSK5764227, for relapsed/refractory extensive-stage small-cell lung cancer.
GSK gets fast-track approval from FDA for Chinese lung cancer drug
02:37am, Tuesday, 20'th Aug 2024
GSK PLC (LSE:GSK, NYSE:GSK) has received the green light for a speedier US regulatory process for a potential new cancer drug being developed with a Chinese partner. The pharmaceuticals developer sa
Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings
01:57pm, Monday, 19'th Aug 2024
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comp
GSK's discount unwarranted, especially with latest Zantac win, says broker
08:51am, Friday, 16'th Aug 2024
British pharma multinational GSK PLC (LSE:GSK, NYSE:GSK) has persistently been undervalued against its international peer set due to merited fears over the high-profile Zantac litigation. But with rec
GSK to seek dismissal of Florida case against heartburn drug Zantac
04:42am, Friday, 16'th Aug 2024
British drugmaker GSK said on Friday it would seek a dismissal of an upcoming Zantac case in Florida, where plaintiffs alleged that its discontinued heart burn drug had caused prostate cancer.
GSK wins favourable ruling in US Zantac litigation
02:50am, Friday, 16'th Aug 2024
GSK PLC (LSE:GSK, NYSE:GSK) has secured a legal victory in the ongoing Zantac (ranitidine) litigation, with the Florida State court in the US excluding the plaintiffs' expert testimony as unreliable.
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
07:30am, Thursday, 15'th Aug 2024
Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's mRNA platform Initiated strategic workforce reduction of
GSK (GSK) is a Top-Ranked Momentum Stock: Should You Buy?
10:50am, Tuesday, 13'th Aug 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
